Coherus Oncology (CHRS) Shares Outstanding (2012 - 2026)

Coherus Oncology has disclosed Shares Outstanding (Entity) across 15 years of filings, most recently posting $154.5 million for Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 32.91% year-over-year to $154.5 million; the TTM figure through Jun 2026 stood at $154.5 million (up 32.91% YoY), while the FY2025 annual figure was $121.2 million, up 4.79% from the prior year.
• Shares Outstanding (Entity) came in at $154.5 million for Q2 2026 at Coherus Oncology, roughly flat from $154.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $154.5 million in Q2 2026 to a low of $77.3 million in Q1 2022.
• Average Shares Outstanding (Entity) over 5 years is $108.1 million, with a median of $114.3 million recorded in 2024.
• Year-over-year, Shares Outstanding (Entity) jumped 42.31% in 2023 and rose 0.89% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $78.9 million in 2022, then soared by 42.31% to $112.2 million in 2023, then advanced by 3.03% to $115.6 million in 2024, then climbed by 4.79% to $121.2 million in 2025, then rose by 27.5% to $154.5 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $154.5 million in Q2 2026, $154.2 million in Q1 2026, and $121.2 million in Q4 2025.